Oppenheimer Lowers Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $15.00

Inovio Pharmaceuticals (NASDAQ:INO) had its price target reduced by analysts at Oppenheimer from $33.00 to $15.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target points to a potential upside of 252.11% from the stock’s current price.

Separately, Royal Bank of Canada lowered their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Friday. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $40.00.

Inovio Pharmaceuticals Price Performance

INO stock opened at $4.26 on Monday. The company has a 50 day simple moving average of $5.75 and a 200 day simple moving average of $8.14. The stock has a market cap of $110.59 million, a price-to-earnings ratio of -1.18 and a beta of 0.83. Inovio Pharmaceuticals has a 1 year low of $4.20 and a 1 year high of $14.75.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in Inovio Pharmaceuticals by 6.7% in the 3rd quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock valued at $3,594,000 after acquiring an additional 38,833 shares during the period. Barclays PLC increased its position in Inovio Pharmaceuticals by 282.6% in the 3rd quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company’s stock valued at $197,000 after acquiring an additional 25,116 shares during the period. Wellington Management Group LLP acquired a new position in Inovio Pharmaceuticals in the 3rd quarter valued at approximately $379,000. State Street Corp increased its position in Inovio Pharmaceuticals by 11.7% in the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock valued at $2,836,000 after acquiring an additional 51,414 shares during the period. Finally, Atom Investors LP acquired a new position in Inovio Pharmaceuticals in the 3rd quarter valued at approximately $103,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.